Forward Science’s non-opioid oral pain relief gel, Orapeutic ™, has received FDA clearance, the company announced in a press release this week.
Orapeutic Oral Pain Gel is manufactured to manage the pain of oral wounds, mouth sores, injuries, and ulcers of the oral mucosa. The gel also maintains a moist wound environment.
“We are proud of our previously released products and their impact on the healthcare industry, but our R&D team is always striving to develop products that meet market demands,” said Forward Science co-founder and Chief Technology Officer Brian Pikkula, PhD. “With the success of our previous product launches, we have become the industry’s leader of innovative solutions in oral healthcare. We are thrilled to receive FDA clearance for Orapeutic and are looking forward to hearing from clinicians as to how this product impacts their patients.”
With concerns of opioids being over-prescribed, Forward Science feels Orapeutic can address the epidemic by offering a pain management alternative. This is the third FDA-cleared product for the company.
Based in Houston, Forward Science is a MedTech company that focuses on moving science forward in the oral care industry. For more information, visit forwardscience.com.
Oral Health Pavilion at HLTH 2024 Highlighted Links Between Dental and General Health
November 4th 2024At HLTH 2024, CareQuest, Colgate-Palmolive, Henry Schein, and PDS Health launched an Oral Health Pavilion to showcase how integrating oral and general health can improve patient outcomes and reduce costs.
Episode 31: Dentsply Sirona Implant Announcements
September 30th 2021DPR’s Editorial Director Noah Levine sat down with Gene Dorff, Dentsply Sirona’s group vice president of implants and Dr. Dan Butterman to review several big announcements the company made in the arena of implants during Dentsply Sirona World 2021 in Las Vegas.